Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ProPhase LabsPRPH +42.29% Days Payable is 1,416.25 as of Mar. 2026, which is 1922% above its 10-year median of 70.03. The stock has 5 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, ProPhase Labs ranks better than 95.79% on this metric.
The historical rank and industry rank for ProPhase Labs's Days Payable or its related term are showing as below:
PRPH'
s Days Payable Range Over the Past 10 Years
Min: 21.84 Med: 70.03 Max: 1736.13
Current: 1736.13
During the past 13 years, ProPhase Labs's highest Days Payable was 1736.13. The lowest was 21.84. And the median was 70.03.
PRPH's Days Payable is ranked better than 95.79% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 64.795
vs PRPH: 1736.13
ProPhase Labs's Days Payable
increased
from Mar. 2025 (1,363.36) to Mar. 2026 (1,416.25).
It may suggest that ProPhase Labsdelayed paying its suppliers.
The historical data trend for ProPhase Labs's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRPH vs IDTA, NSTM, NOTVQ: Days Payable Comparison
For the Diagnostics & Research subindustry, ProPhase Labs's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProPhase Labs Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Days Payable distribution charts can be found below:
* The bar in red indicates where ProPhase Labs's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
ProPhase Labs's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProPhase Labs (PRPH) has a Days Payable of 1,416.25 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ProPhase Labs and its competitors. This is 1922% above median its historical median of 70.03. Over the past decade, ProPhase Labs' Days Payable has ranged from 21.84 to 1,736.13. According to the industry distribution chart, ProPhase Labs ranks #8 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 4.2%.
Is ProPhase Labs' Days Payable too high?
ProPhase Labs' current Days Payable of 1,416.25 is 1922% above median its 10-year median of 70.03. Over the past 10 years, this metric has ranged from a low of 21.84 to a high of 1,736.13. The Medical Diagnostics & Research industry median Days Payable is 64.80. ProPhase Labs' value of 1,416.25 is 2085.7% above this industry median. Based on the distribution chart, ProPhase Labs ranks #8 out of 190 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does ProPhase Labs' Days Payable compare to IDTA and NSTM?
According to the Medical Diagnostics & Research industry distribution chart, ProPhase Labs ranks #8 out of 190 companies for Days Payable. This places ProPhase Labs in the top 4% of its industry — outperforming the majority of peers. The industry median Days Payable is 64.80. ProPhase Labs' value of 1,416.25 is 2085.7% above this benchmark. Historically, ProPhase Labs' own Days Payable has ranged from 21.84 to 1,736.13 over the past decade. While the company's 10-year median is 70.03 vs. the industry median of 64.80, ProPhase Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.80, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ProPhase Labs's current Days Payable of 1,416.25 is 2085.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ProPhase Labs and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProPhase Labs's current Days Payable is 1,416.25, which is 1922% above median its own 10-year median of 70.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.90, compared to a current price of $0.05 — trading 94.5% below its estimated fair value. The current Days Payable is 1,416.25, which is 1922% above median its 10-year median of 70.03 and 2085.7% above the Medical Diagnostics & Research industry median of 64.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current Days Payable is 1,416.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRPH has been successfully added to your 
